Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retapamulin Ointment for S. aureus Nasal Colonization
NCT00539994Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2007
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of retapamulin in Staphylococcus aureus nasal colonization (3 arms), sponsored by GSK. Primary endpoints: Plasma Retapumulin Pharmacokinetic Parameters Evaluated by Plasma AUC After Dosing at Day 5, Plasma Retapumulin Pharmacokinetic Parameters Evaluated by Plasma Cmax After Dosing at Day 5 and 1 more. Started Sep 2007; status: completed.
02
Drugs
retapamulin
03
Conditions
Staphylococcus aureus nasal colonization
Beyond the preview
Go deeper on NCT00539994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00539994.